News Biogen Inc. Xetra

Equities

IDP

US09062X1037

Market Closed - Xetra Other stock markets 09:05:35 22/05/2024 pm IST			After market 11:46:17 pm
207.2 ^EUR	-0.91%		209.2	+0.97%

08:03pm	Sector Update: Health Care Stocks Advance Wednesday Afternoon	MT
07:38pm	Sector Update: Health Care	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Advance Wednesday Afternoon	11:33pm	MT
Sector Update: Health Care	11:08pm	MT
Biogen Agrees to Buy Human Immunology Biosciences For up to $1.8 Billion	10:14pm	MT
Top Midday Stories: US Targets August 1 Start Date for China Tariff Hikes; CFPB Says BNPL Requires Credit Card-Level Oversight; Target Shares Fall on Earnings Miss; Third BHP Bid Rejected by Anglo American	10:03pm	MT
Wedbush Raises Biogen Price Target to $219 From $215, Maintains Neutral Rating	07:28pm	MT
Biogen: agreement to acquire HI-Bio	07:03pm	CF
Biogen to Acquire Human Immunology Biosciences for up to $1.8 Billion	05:48pm	MT
Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal	05:07pm	RE
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences	05:00pm	GL
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	17/05	MT
Sector Update: Health Care Stocks Ease Thursday Afternoon	16/05	MT
US Equity Indexes Trade Mixed as Investors Weigh Macro Data; Dow Touches Record High	16/05	MT
Sector Update: Health Care	16/05	MT
Dow Touches 40,000 Mark for First Time as Macroeconomic Data Signals Economic Weakness	16/05	MT
Ionis Pharmaceuticals Says Potential Angelman Syndrome Therapy Improves Symptoms in Phase 1/2a Study	16/05	MT
Stocks in motion: Walmart, Chubb, Deere...	16/05
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status	16/05	AQ
Sector Update: Health Care Stocks Steady Premarket Thursday	16/05	MT
Biogen, Ionis to Cease BIIB105 ALS Investigational Drug Development Following Phase 1/2 Trial Results	16/05	MT
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis	16/05	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biogen Inc. Xetra

Equities

IDP

US09062X1037

Summary

Filters